Background

Validated chronic migraine biomarkers could improve diagnostic, prognostic, and predictive abilities for clinicians and researchers, as well as increase knowledge on migraine pathophysiology.

Objective

The objective of this narrative review is to summarise and interpret the published literature regarding the current state of development of chronic migraine biomarkers.

Findings

Data from functional and structural imaging, neurophysiological, and biochemical studies have been utilised towards the development of chronic migraine biomarkers. These biomarkers could contribute to chronic migraine classification/diagnosis, prognosticating patient outcomes, predicting response to treatment, and measuring treatment responses early after initiation. Results show promise for using measures of brain structure and function, evoked potentials, and sensory neuropeptide concentrations for the development of chronic migraine biomarkers, yet further optimisation and validation are still required.

Conclusions

Imaging, neurophysiological, and biochemical changes that occur with the progression from episodic to chronic migraine could be utilised for developing chronic migraine biomarkers that might assist with diagnosis, prognosticating individual patient outcomes, and predicting responses to migraine therapies. Ultimately, validated biomarkers could move us closer to being able to practice precision medicine in the field and thus improve patient care.

中文翻译：

---

慢性偏头痛患者的大脑如何变化？开发疾病生物标志物

背景

经过验证的慢性偏头痛生物标志物可以提高临床医生和研究人员的诊断、预后和预测能力，并增加对偏头痛病理生理学的了解。

客观的

本叙述性综述的目的是总结和解释已发表的关于慢性偏头痛生物标志物发展现状的文献。

发现

来自功能和结构成像、神经生理学和生化研究的数据已被用于开发慢性偏头痛生物标志物。这些生物标志物可能有助于慢性偏头痛的分类/诊断、预测患者结果、预测对治疗的反应以及在开始后早期测量治疗反应。结果表明，使用大脑结构和功能、诱发电位和感觉神经肽浓度的测量来开发慢性偏头痛生物标志物是有希望的，但仍需要进一步优化和验证。

结论

随着从发作性偏头痛到慢性偏头痛的进展而发生的影像学、神经生理学和生化变化可用于开发可能有助于诊断、预测个体患者结果和预测对偏头痛治疗的反应的慢性偏头痛生物标志物。最终，经过验证的生物标志物可以使我们更接近于在该领域实施精准医学，从而改善患者护理。